ARTICLE | Company News
Saforis gets Priority Review
June 13, 2006 1:18 AM UTC
FDA accepted for filing and granted Priority Review to an NDA from MGI Pharma (MOGN) for Saforis oral suspension to treat and prevent oral mucositis in patients receiving mucotoxic cancer therapy. The...